カテゴリ： GlobalData, インド, 企業調査

Lupin Ltd (LUPIN)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Lupin Ltd (LUPIN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C10042
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：97
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：インド
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Lupin Ltd (Lupin) focuses on the development and manufacture of generic and branded formulations, biotechnology products and active pharmaceutical ingredients (APIs). The company has expertise in the areas of cardiovascular, asthma, diabetology, pediatrics, central nervous system, gastro-intestinal, anti-infectives, nonsteroidal anti-inflammatory drugs (NSAIDs), anti-TB and cephalosporins. It undertakes extensive research and development of pharmaceuticals for treatment of migraine, gastrointestinal, psoriasis, central nervous system, cardiovascular, tuberculosis, diabetes and inflammation. Lupin develops value-added generic pharmaceuticals based on its platform technologies. The company along with its subsidiaries has manufacturing facilities in India, the US, Japan, Mexico and Brazil. Lupin is headquartered in Mumbai, Maharashtra, India.

Lupin Ltd (LUPIN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Lupin Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Lupin Ltd, Medical Devices Deals, 2012 to YTD 2018 12
Lupin Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Lupin Ltd, Pharmaceuticals & Healthcare, Deal Details 15
Asset Purchase 15
Kyowa Pharma to Acquire 21 Products from Shionogi 15
Lupin to Acquire Product Portfolio from Temmler Pharma 16
Lupin Plans To Acquire US Branded Drugs 17
Venture Financing 18
Symbiomix Therapeutics Raises USD6 Million in Venture Financing 18
Symbiomix Therapeutics Raises USD41 Million in Series A Financing 19
Symbiomix Therapeutics Raises USD20 Million in Venture Financing 20
Private Equity 21
Bayer May Sell Dermatology Business 21
Partnerships 22
Lupin and Mylan Enter into Partnership Agreement 22
Lupin and Nichi-Iko Enter into Partnership Agreement 23
Lupin, CSIR-National Chemical Laboratory and DST Enter into Research Agreement 24
Astellas Pharma Enters into Distribution Agreement with Kyowa Pharma 25
Boehringer Ingelheim Expands Co-Marketing Agreement with Lupin 26
Lupin Enters into Co-Marketing Agreement with Novartis Healthcare 27
Lupin and Boehringer Ingelheim Enters into Co-marketing Agreement 28
Lupin Enters into Development Agreement with Celon for Generic Advair Diskus 29
Lupin Enters into Co-Development Agreement with Merck Serono 30
Lupin Enters into Distribution Agreement with Salix Pharma 31
Lupin Enters into Distribution Agreement with LG Life Sciences for Insulin Analogue Glargine 32
Lupin Enters Into Joint Venture Agreement With Yoshindo To Form YL Biologics 33
Gavis Pharma Partners with Modavar Pharma 34
Lupin Enters Into Co-Promotion Agreement With Onset Dermatologics For Locoid Lotion 35
Licensing Agreements 36
Lupin Enters into Licensing Agreement with Eli Lilly and Company 36
Lupin Pharma Enters into Licensing Agreement with MonoSol Rx 37
Lupin Enters into Licensing Agreement with Medicines Patent Pool 38
Romark Labs Enters Into Licensing Agreement With Lupin For Alinia 39
Merck Enters Into Licensing Agreement With Lupin 40
Equity Offering 41
Lupin Plans to Raise USD1.2 Billion in Public Offering of Equity Securities 41
Asset Transactions 42
G&W Labs to Acquire Two Generic Drugs of Gavis Pharma from Lupin 42
Lupin to Acquire Product Portfolio from Temmler Pharma 43
Acquisition 44
Lupin Pharma Acquires Symbiomix Therapeutics 44
Lupin Acquires GAVIS Pharma for USD880 Million 45
Lupin Acquires Biocom 46
Lupin Acquires Medquimica 47
Lupin to Acquire Remaining 40% Stake in Pharma Dynamics 48
Lupin Acquires Labs Grin, Ophthalmology Therapies Provider 49
Lupin Plans to Acquire Generics Manufacturing Companies In Europe for up to USD1 Billion 50
Lupin Acquires Nanomi 51
Gavis Pharma Revises Open Offer Price To Acquire Additional 26% Stake In Wintac For US$5 Million 52
Aenova Completes Acquisition Of Temmler Pharma, Contract Manufacturing Company 53
Lupin Ltd – Key Competitors 54
Lupin Ltd – Key Employees 55
Lupin Ltd – Locations And Subsidiaries 57
Head Office 57
Other Locations & Subsidiaries 57
Joint Venture 60
Recent Developments 61
Strategy And Business Planning 61
May 09, 2017: Lupin Announces Opening of its new 100,000 square foot expansion at its Somerset, NJ Manufacturing Site 61
Financial Announcements 62
Oct 31, 2018: Lupin quarter II, FY2019 – results 62
Aug 08, 2018: LUPIN: Quarter I, FY2019 -results 64
May 15, 2018: Lupin announces fiscal year 2018 Results, Board recommends dividend of 250% 66
Feb 06, 2018: Lupin Quarter III, FY2018-Results 68
Oct 30, 2017: Lupin Quarter II, FY2018 – Results 70
May 24, 2017: Lupin Announces Quarter IV and Annual Results, FY2017 72
Feb 09, 2017: Lupin Quarter III Results, FY2017 74
Corporate Communications 76
Sep 18, 2018: Lupin appoints Alok Sonig as CEO – US Generics and Global Head – Generics R&D & Biosimilars 76
May 31, 2018: Lupin appoints Nicholas Hart as President – Specialty for US Business 77
Sep 18, 2017: Lupin appoints Jim Loerop as Chief Corporate Development Officer 78
Legal and Regulatory 79
Oct 19, 2018: Lupin’s Pithampur unit-3 (Indore) inspected by US FDA 79
Sep 14, 2018: Lupin’s Nagpur facility inspection by US FDA concluded with no observation 80
Sep 04, 2018: Lupin’s Tarapur API Manufacturing Facility Inspected by US FDA 81
Aug 24, 2018: Lupin’s Nagpur facility receives Establishment Inspection Report from US FDA 82
Jul 30, 2018: Lupin’s mandideep facility gets approval from EDQM 83
Jul 16, 2018: Lupin’s Goa facility gets approval from UK MHRA 84
May 14, 2018: Lupin’s Nagpur facility US FDA inspection concluded with no observations 85
Apr 06, 2018: Lupin’s Pithampur Unit 1 facility receives Establishment Investigation report (EIR) from US FDA 86
Apr 03, 2018: Lupin’s Goa facility completes successful UK MHRA inspection 87
Apr 02, 2018: Lupin’s Pithampur Unit cleared by Health Canada 88
Aug 21, 2017: Lupin receives EIR from US FDA for Aurangabad, April 2017 Inspection 89
Jul 31, 2017: Lupin’s Aurangabad facility inspection concluded by US FDA 90
Jul 28, 2017: Lupin’s Pithampur facility inspection concluded by US FDA without any observations 91
Government and Public Interest 92
Jun 29, 2018: Lupin announces tie-up with European Association of Urology (EAU) 92
Product News 93
05/27/2017: Lupin Pharmaceuticals Announces a Nationwide Recall of Mibelas 24 Fe (Norethindrone Acetate and Ethinyl Estradiol 1mg/0.02mg Chewable Tablets and Ferrous Fumarate 75mg) Tablets 93
May 10, 2018: Lupin launches Corcal Bone and Beauty supplement 94
03/16/2017: Lupin launches Generic Minastrin 24 Fe chewable tablets in the US 95
Other Significant Developments 96
Jul 21, 2017: Lupin’s Goa facility inspection concluded by US FDA without any observations 96
Appendix 97
Methodology 97
About GlobalData 97
Contact Us 97
Disclaimer 97

List of Tables
Lupin Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Lupin Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Lupin Ltd, Deals By Therapy Area, 2012 to YTD 2018 10
Lupin Ltd, Medical Devices Deals, 2012 to YTD 2018 12
Lupin Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Kyowa Pharma to Acquire 21 Products from Shionogi 15
Lupin to Acquire Product Portfolio from Temmler Pharma 16
Lupin Plans To Acquire US Branded Drugs 17
Symbiomix Therapeutics Raises USD6 Million in Venture Financing 18
Symbiomix Therapeutics Raises USD41 Million in Series A Financing 19
Symbiomix Therapeutics Raises USD20 Million in Venture Financing 20
Bayer May Sell Dermatology Business 21
Lupin and Mylan Enter into Partnership Agreement 22
Lupin and Nichi-Iko Enter into Partnership Agreement 23
Lupin, CSIR-National Chemical Laboratory and DST Enter into Research Agreement 24
Astellas Pharma Enters into Distribution Agreement with Kyowa Pharma 25
Boehringer Ingelheim Expands Co-Marketing Agreement with Lupin 26
Lupin Enters into Co-Marketing Agreement with Novartis Healthcare 27
Lupin and Boehringer Ingelheim Enters into Co-marketing Agreement 28
Lupin Enters into Development Agreement with Celon for Generic Advair Diskus 29
Lupin Enters into Co-Development Agreement with Merck Serono 30
Lupin Enters into Distribution Agreement with Salix Pharma 31
Lupin Enters into Distribution Agreement with LG Life Sciences for Insulin Analogue Glargine 32
Lupin Enters Into Joint Venture Agreement With Yoshindo To Form YL Biologics 33
Gavis Pharma Partners with Modavar Pharma 34
Lupin Enters Into Co-Promotion Agreement With Onset Dermatologics For Locoid Lotion 35
Lupin Enters into Licensing Agreement with Eli Lilly and Company 36
Lupin Pharma Enters into Licensing Agreement with MonoSol Rx 37
Lupin Enters into Licensing Agreement with Medicines Patent Pool 38
Romark Labs Enters Into Licensing Agreement With Lupin For Alinia 39
Merck Enters Into Licensing Agreement With Lupin 40
Lupin Plans to Raise USD1.2 Billion in Public Offering of Equity Securities 41
G&W Labs to Acquire Two Generic Drugs of Gavis Pharma from Lupin 42
Lupin to Acquire Product Portfolio from Temmler Pharma 43
Lupin Pharma Acquires Symbiomix Therapeutics 44
Lupin Acquires GAVIS Pharma for USD880 Million 45
Lupin Acquires Biocom 46
Lupin Acquires Medquimica 47
Lupin to Acquire Remaining 40% Stake in Pharma Dynamics 48
Lupin Acquires Labs Grin, Ophthalmology Therapies Provider 49
Lupin Plans to Acquire Generics Manufacturing Companies In Europe for up to USD1 Billion 50
Lupin Acquires Nanomi 51
Gavis Pharma Revises Open Offer Price To Acquire Additional 26% Stake In Wintac For US$5 Million 52
Aenova Completes Acquisition Of Temmler Pharma, Contract Manufacturing Company 53
Lupin Ltd, Key Competitors 54
Lupin Ltd, Key Employees 55
Lupin Ltd, Other Locations 57
Lupin Ltd, Subsidiaries 57
Lupin Ltd, Joint Venture 60

List of Figures
Lupin Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Lupin Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Lupin Ltd, Medical Devices Deals, 2012 to YTD 2018 12

★海外企業調査レポート[Lupin Ltd (LUPIN)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • CRH Medical Corp (CRH)：企業の財務・戦略的SWOT分析
    Summary CRH Medical Corp (CRH Medical), is a medical device company that offers treatment of hemorrhoids. The company provides CRH O’Regan System, a hemorrhoid technology for treating hemorrhoid. It offers topical ointments and creams including preparation H for the treatment of hemorrhoid. CRH Medi …
  • Marfin Investment Group Holdings S.A.：企業のM&A・事業提携・投資動向
    Marfin Investment Group Holdings S.A. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Marfin Investment Group Holdings S.A. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed report …
  • Partners HealthCare System Inc-製薬・医療分野：企業M&A・提携分析
    Summary Partners HealthCare System Inc (PHS) is a nonprofit integrated health care organization. It operates a network of community and specialty hospitals, a physician network, managed care organizations, home health and long-term care centers, community health centers and other health care entitie …
  • OncBioMune Pharmaceuticals Inc (OBMP)：企業の財務・戦略的SWOT分析
    Summary OncBioMune Pharmaceuticals Inc (OncBioMune), formerly Quint Media Inc is a biopharmaceutical company that develops novel cancer immunotherapy products. The company’s products comprise biosimilars and vaccines developed for cancer types such as renal, breast, prostrate, and ovarian cancer. It …
  • Taghleef Industries L.L.C.
    Taghleef Industries L.L.C. - Strategy, SWOT and Corporate Finance Report Summary Taghleef Industries L.L.C. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Allena Pharmaceuticals Inc (ALNA)：製薬・医療：M&Aディール及び事業提携情報
    Summary Allena Pharmaceuticals Inc (Allena) is a developer of oral enzyme therapeutics to treat patients with rare and severe metabolic disorders. The company develops ALLN-177, an oral recombinant oxalate degrading enzyme. It provides ALLN-177 which is developed for the chronic management of hypero …
  • Starbreeze AB (STAR B)：企業の財務・戦略的SWOT分析
    Summary Starbreeze AB (Starbreeze) is a game development company that creates, publishes and distributes entertainment products and games. The company’s published games include the outforce, enclave, knights of the temple, syndicate, the chronicles of riddick, knights of the temple, enclave, escapes …
  • Takara Holdings Inc.：企業の戦略・SWOT・財務情報
    Takara Holdings Inc. - Strategy, SWOT and Corporate Finance Report Summary Takara Holdings Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • The Schwan Food Company：戦略・SWOT・企業財務分析
    The Schwan Food Company - Strategy, SWOT and Corporate Finance Report Summary The Schwan Food Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Aeras Global TB Vaccine Foundation Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Aeras Global TB Vaccine Foundation Inc (Aeras) is a non-profit biotech organization that develops tuberculosis (TB) vaccines. The organization offers TB vaccine candidates, preclinical candidates and vaccine candidates. Its services include portfolio management, preclinical research, clinica …
  • Green Cross Cell Corp (031390)：企業の財務・戦略的SWOT分析
    Green Cross Cell Corp (031390) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • BlackRock Inc：企業の戦略・SWOT・財務情報
    BlackRock Inc - Strategy, SWOT and Corporate Finance Report Summary BlackRock Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Origin Enterprises PLC：企業のM&A・事業提携・投資動向
    Origin Enterprises PLC - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Origin Enterprises PLC Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • Bioanalytical Systems Inc (BASI)：企業の財務・戦略的SWOT分析
    Summary Bioanalytical Systems Inc (Bioanalytical Systems) is a contract research organization that provides drug discovery and development services, and analytical instruments. The company’s contract research services include screening and pharmacological testing, formulation development, preclinica …
  • New China Life Insurance Company Ltd.
    New China Life Insurance Company Ltd. - Strategy, SWOT and Corporate Finance Report Summary New China Life Insurance Company Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Glencore Plc：企業のM&A・事業提携・投資動向
    Glencore Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Glencore Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Sterling Holiday Resorts (India) Limited：企業の戦略・SWOT・財務情報
    Sterling Holiday Resorts (India) Limited - Strategy, SWOT and Corporate Finance Report Summary Sterling Holiday Resorts (India) Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Mahanagar Telephone Nigam Ltd (MTNL)：企業の財務・戦略的SWOT分析
    Mahanagar Telephone Nigam Ltd (MTNL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Apollo Consolidated Ltd (AOP)：企業の財務・戦略的SWOT分析
    Summary Apollo Consolidated Ltd (Apollo) is a mining and mineral exploration company. The company’s business activities include acquisition, exploration, and development of gold, copper and nickel mineral deposits. Apollo holds exploration permits in Western Australia and Western Africa. The company …
  • Butterfield Private Banking：企業の戦略・SWOT・財務情報
    Butterfield Private Banking - Strategy, SWOT and Corporate Finance Report Summary Butterfield Private Banking - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆